Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.
Thermo Fisher Scientific announced on Sept. 8, 2021 plans to establish a dedicated single-use technologies (SUT) product manufacturing facility in Nashville, Tenn. The facility, which is expected to begin construction by the second quarter of 2022, will more than double the company’s current SUT manufacturing capacity.
The Nashville site is part of a more than $650 million investment into bioprocessing production capabilities expansions, which are set to take place across 11 manufacturing sites in North America, Europe, and Asia. The investment also includes expansion projects in Logan, Utah, and Suzhou, China, along with a new SUT manufacturing site in Singapore.
The $650 million investment program also expands global production capabilities in additional bioprocessing manufacturing networks. Capacity expansion projects in Grand Island, NY, Miami, Fla., and Inchinnan, Scotland, will increase production of cell culture media (Gibco), supplements, and process liquids, as well as the manufacturing of customer-owned proprietary media formulations.
"Over the last few years, more and more biological drugs and vaccines are being manufactured utilizing the single-use platform. This has created incredible demand for our SUT products," said Michel Lagarde, executive vice-president of Thermo Fisher Scientific, in a company press release. "The site in Nashville will be critical in Thermo Fisher's global network to continue to support the biopharma industry's work in developing life-saving biologics and vaccines."
Source: Thermo Fisher Scientific
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.